Ting Niu

5.3k total citations
230 papers, 3.0k citations indexed

About

Ting Niu is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Ting Niu has authored 230 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 106 papers in Hematology, 89 papers in Molecular Biology and 77 papers in Oncology. Recurrent topics in Ting Niu's work include Multiple Myeloma Research and Treatments (40 papers), Acute Myeloid Leukemia Research (33 papers) and CAR-T cell therapy research (29 papers). Ting Niu is often cited by papers focused on Multiple Myeloma Research and Treatments (40 papers), Acute Myeloid Leukemia Research (33 papers) and CAR-T cell therapy research (29 papers). Ting Niu collaborates with scholars based in China, United States and Canada. Ting Niu's co-authors include Jing Xu, Jinrong Yang, Ting Liu, Jun Li, Taixing Cui, Xing Li Wang, Ailin Zhao, Joseph S. Janicki, Lijuan Chen and Dongqi Tang and has published in prestigious journals such as Nucleic Acids Research, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Ting Niu

200 papers receiving 2.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ting Niu China	27	1.3k	963	800	607	344	230	3.0k
Lei Gao China	25	711 0.5×	667 0.7×	986 1.2×	562 0.9×	467 1.4×	170	2.4k
Bing Xu China	31	1.5k 1.2×	386 0.4×	693 0.9×	452 0.7×	166 0.5×	192	3.1k
Xi Zhang China	32	1.8k 1.4×	1.4k 1.5×	1.8k 2.2×	1.0k 1.7×	631 1.8×	274	4.6k
Heiko van der Kuip Germany	30	1.0k 0.8×	462 0.5×	1.3k 1.6×	249 0.4×	326 0.9×	60	2.8k
Chris Tselepis United Kingdom	33	1.2k 0.9×	720 0.7×	620 0.8×	237 0.4×	402 1.2×	71	3.2k
Bor‐Sheng Ko Taiwan	32	1.7k 1.3×	1.3k 1.3×	435 0.5×	259 0.4×	910 2.6×	141	3.8k
Ciprian Tomuleasa Romania	26	1.3k 1.0×	340 0.4×	552 0.7×	336 0.6×	252 0.7×	181	2.6k
Jean‐Pierre Vannier France	28	738 0.6×	381 0.4×	605 0.8×	387 0.6×	207 0.6×	81	2.5k
Jing Chen China	29	969 0.7×	1.1k 1.1×	971 1.2×	651 1.1×	334 1.0×	172	3.1k
Germana Castelli Italy	29	1.6k 1.3×	431 0.4×	798 1.0×	400 0.7×	336 1.0×	97	3.1k

Countries citing papers authored by Ting Niu

Since Specialization

Citations

This map shows the geographic impact of Ting Niu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ting Niu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ting Niu more than expected).

Fields of papers citing papers by Ting Niu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ting Niu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ting Niu. The network helps show where Ting Niu may publish in the future.

Co-authorship network of co-authors of Ting Niu

This figure shows the co-authorship network connecting the top 25 collaborators of Ting Niu. A scholar is included among the top collaborators of Ting Niu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ting Niu. Ting Niu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shen, Kai, Yi‐Jen Liao, Yang Dai, et al.. (2025). Integration of anti-PD-1 antibody into chemotherapeutic regimens improved the outcome of aggressive NK cell leukemia: a single-center retrospective real-world analysis. Frontiers in Immunology. 16. 1576904–1576904.

Li, Hexian, Qizhong Lu, Zhengyu Yu, et al.. (2025). CRISPR/Cas9-engineered universal CD123/B7-H3 tandem CAR-T cell for the treatment of acute myeloid leukemia. Chinese Medical Journal. 139(5). 728–740.

Yang, Yuqi, Yijun Wu, Kai Kang, et al.. (2024). Transformation risk and associated survival outcome of marginal zone lymphoma: A nationwide study. Annals of Hematology. 103(10). 4211–4222. 2 indexed citations

Zhao, Lei, Hongbing Ma, Ting Niu, et al.. (2024). Myelomonocytic and monocytic acute myeloid leukemia demonstrate comparable poor outcomes with venetoclax-based treatment: a monocentric real-world study. Annals of Hematology. 103(4). 1197–1209. 5 indexed citations

Chen, Lijuan, et al.. (2024). First-in-Human Phase I/IIa Safety and Efficacy of Flonoltinib Maleate, a New Generation of JAK2/FLT3 Inhibitor in Myelofibrosis. Blood. 144(Supplement 1). 486–486.

Yu, Zhengyu, Aiping Tong, & Ting Niu. (2024). Fc Receptor-like 5 (FCRL5)-Directed CAR-T Cells Exhibit Antitumor Activity Against Multiple Myeloma. Blood. 144(Supplement 1). 7091–7091. 1 indexed citations

Li, Yan, et al.. (2024). Modest survival benefits of autologous stem cell transplantation in multiple myeloma with renal impairment: a critical appraisal of the pre-antibody era. Clinical and Experimental Medicine. 24(1). 215–215.

Huang, Liang, Heng Mei, Yuhua Li, et al.. (2024). Real-world experience of commercial relmacabtagene autoleucel (relma-cel) for relapsed/refractory central nervous system lymphoma: a multicenter retrospective analysis of patients in China. Journal for ImmunoTherapy of Cancer. 12(5). e008553–e008553. 10 indexed citations

Yu, Zhengyu, et al.. (2023). Characterization and application of a lactate and branched chain amino acid metabolism related gene signature in a prognosis risk model for multiple myeloma. Cancer Cell International. 23(1). 169–169. 14 indexed citations

10.

Wu, Mengrui, et al.. (2023). Nutritional Status Indices and Monoclonal Gammopathy of Undetermined Significance Risk in the Elderly Population: Findings from the National Health and Nutrition Examination Survey. Nutrients. 15(19). 4210–4210. 6 indexed citations

11.

Zhang, Hang, Xinchuan Chen, Dong Tian, et al.. (2023). Short-Term Blinatumomab As a Bridge Therapy for Hematopoietic Stem Cell Transplantation in B-Cell Acute Lymphoblastic Leukemia with Low Leukemia Burden. Blood. 142(Supplement 1). 234–234.

12.

Zeng, Qiang, Hang Zhang, Jian Li, et al.. (2023). The MAGIC algorithm probability (MAP)‐guided preemptive therapy of acute graft versus host disease with methylprednisolone: A randomized controlled trial. American Journal of Hematology. 98(10). 1550–1558. 1 indexed citations

13.

Zeng, Qiang, Bingyang Chu, Zhigang Liu, et al.. (2023). Melphalan-loaded methoxy poly(ethylene glycol)-poly(d,l-lactide) copolymer nanomicelles in the treatment of multiple myeloma. Chinese Chemical Letters. 34(9). 108133–108133. 10 indexed citations

14.

Yang, Tao, Ailin Zhao, Mingsong Shi, et al.. (2022). Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2V617F-induced myeloproliferative neoplasms. Blood Cancer Journal. 12(3). 37–37. 9 indexed citations

15.

Qiu, Qiang, Minghai Tang, Fang Wang, et al.. (2019). Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of BCR-ABL –Induced B-Cell Acute Lymphoblastic Leukemia. Clinical Cancer Research. 25(24). 7527–7539. 16 indexed citations

16.

Yuan, Xue, Yong Chen, Jun He, et al.. (2019). Identification of Pyrrolo[2,3-d]pyrimidine-Based Derivatives as Potent and Orally Effective Fms-like Tyrosine Receptor Kinase 3 (FLT3) Inhibitors for Treating Acute Myelogenous Leukemia. Journal of Medicinal Chemistry. 62(8). 4158–4173. 31 indexed citations

17.

Zhang, Chufeng, Heying Pei, Jun He, et al.. (2019). Design, synthesis and evaluation of novel 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as potent, selective and reversible Bruton's tyrosine kinase (BTK) inhibitors for the treatment of rheumatoid arthritis. European Journal of Medicinal Chemistry. 169. 121–143. 25 indexed citations

18.

Wang, Fang, Li Zheng, Zhuang Yang, et al.. (2018). SKLB-23bb, A HDAC6-Selective Inhibitor, Exhibits Superior and Broad-Spectrum Antitumor Activity via Additionally Targeting Microtubules. Molecular Cancer Therapeutics. 17(4). 763–775. 21 indexed citations

19.

Chang, Lung‐Ji, Lujia Dong, Jun Zhu, et al.. (2015). 4SCAR19 Chimeric Antigen Receptor-Modified T Cells As a Breakthrough Therapy for Highly Chemotherapy-Resistant Late-Stage B Cell Lymphoma Patients with Bulky Tumor Mass. Blood. 126(23). 264–264. 8 indexed citations

20.

Zhang, Xiao Hui, Ru Feng, Lan Xu, et al.. (2014). Immunosuppressive treatment combined with nucleoside analog is superior to nucleoside analog only in the treatment of severe thrombocytopenia in patients with cirrhosis associated with hepatitis B in China: A multicenter, observational study. Platelets. 26(7). 672–679. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact